378 related articles for article (PubMed ID: 32009006)
21. Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population.
Salerno SN; Carreño FO; Edginton AN; Cohen-Wolkowiez M; Gonzalez D
Drug Metab Dispos; 2021 Sep; 49(9):844-855. PubMed ID: 34154994
[TBL] [Abstract][Full Text] [Related]
22. PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery.
Chen KF; Chan LN; Lin YS
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):493-512. PubMed ID: 32710209
[TBL] [Abstract][Full Text] [Related]
23. A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma.
Khindri S; Cahn A; Begg M; Montembault M; Leemereise C; Cui Y; Hogg A; Wajdner H; Yang S; Robertson J; Hamblin JN; Ludwig-Sengpiel A; Kornmann O; Hessel EM
J Pharmacol Exp Ther; 2018 Dec; 367(3):405-413. PubMed ID: 30217958
[TBL] [Abstract][Full Text] [Related]
24. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
[TBL] [Abstract][Full Text] [Related]
25. Assessment of cytochrome P450 3A4-mediated drug-drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model.
Jing J; Chen Y; Musib L; Jin JY; Cheung KWK; Yoshida K; Sane R
Cancer Chemother Pharmacol; 2022 May; 89(5):707-720. PubMed ID: 35428895
[TBL] [Abstract][Full Text] [Related]
26. Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions.
Boetsch C; Parrott N; Fowler S; Poirier A; Hainzl D; Banken L; Martin-Facklam M; Hofmann C
Clin Pharmacokinet; 2016 Feb; 55(2):237-47. PubMed ID: 26341813
[TBL] [Abstract][Full Text] [Related]
27. A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition.
Li X; Junge L; Taubert M; von Georg A; Dahlinger D; Starke C; Frechen S; Stelzer C; Kinzig M; Sörgel F; Jaehde U; Töx U; Goeser T; Fuhr U
J Clin Pharmacol; 2020 Sep; 60(9):1237-1253. PubMed ID: 32427354
[TBL] [Abstract][Full Text] [Related]
28. Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions.
Prieto Garcia L; Janzén D; Kanebratt KP; Ericsson H; Lennernäs H; Lundahl A
Drug Metab Dispos; 2018 Oct; 46(10):1420-1433. PubMed ID: 30068519
[TBL] [Abstract][Full Text] [Related]
29. Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole.
Lehr T; Staab A; Trommeshauser D; Schaefer HG; Kloft C
Clin Pharmacokinet; 2010; 49(1):53-66. PubMed ID: 20000889
[TBL] [Abstract][Full Text] [Related]
30. Physiologically Based Pharmacokinetic Modelling of Inhaled Nemiralisib: Mechanistic Components for Pulmonary Absorption, Systemic Distribution, and Oral Absorption.
Miller NA; Graves RH; Edwards CD; Amour A; Taylor E; Robb O; O'Brien B; Patel A; Harrell AW; Hessel EM
Clin Pharmacokinet; 2022 Feb; 61(2):281-293. PubMed ID: 34458976
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of drug-drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling.
Ji T; Chen X; Yeleswaram S
CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):894-905. PubMed ID: 35506332
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters.
Katsube T; Inoue Y; Fukuhara T; Kano T; Wajima T
Eur J Clin Pharmacol; 2020 Dec; 76(12):1659-1665. PubMed ID: 32666123
[TBL] [Abstract][Full Text] [Related]
33. A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
Einolf HJ; Zhou J; Won C; Wang L; Rebello S
Drug Metab Dispos; 2017 Apr; 45(4):361-374. PubMed ID: 28122787
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H
Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990
[TBL] [Abstract][Full Text] [Related]
35. PKPD and cardiac single cell modeling of a DDI study with a CYP3A4 substrate and itraconazole to quantify the effects on QT interval duration.
Jaminion F; Bentley D; Wang K; Wandel C; Derks M; Diack C
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):447-459. PubMed ID: 32572738
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P-Glycoprotein Inhibitor (Itraconazole).
Kobayashi K; Abe Y; Kawai A; Furihata T; Endo T; Takeda H
J Clin Pharmacol; 2020 Oct; 60(10):1314-1323. PubMed ID: 32459872
[TBL] [Abstract][Full Text] [Related]
37. Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.
Quinney SK; Zhang X; Lucksiri A; Gorski JC; Li L; Hall SD
Drug Metab Dispos; 2010 Feb; 38(2):241-8. PubMed ID: 19884323
[TBL] [Abstract][Full Text] [Related]
38. Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction.
Chen Y; Ma F; Lu T; Budha N; Jin JY; Kenny JR; Wong H; Hop CE; Mao J
Clin Pharmacokinet; 2016 Jun; 55(6):735-49. PubMed ID: 26692192
[TBL] [Abstract][Full Text] [Related]
39. Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection.
Gajewska M; Blumenstein L; Kourentas A; Mueller-Zsigmondy M; Lorenzo S; Sinn A; Velinova M; Heimbach T
AAPS J; 2020 Oct; 22(6):134. PubMed ID: 33070288
[TBL] [Abstract][Full Text] [Related]
40. Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions.
Einolf HJ; Lin W; Won CS; Wang L; Gu H; Chun DY; He H; Mangold JB
Drug Metab Dispos; 2017 Dec; 45(12):1304-1316. PubMed ID: 28912253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]